Abionyx Pharma SA Cash Flow-to-Debt Ratio
Abionyx Pharma SA cash flow-to-debt ratio. Abionyx Pharma SA (ABNX) has a Cash Flow-to-Debt Ratio of -0.22x as of June 2025, meaning its operating cash flow of €-1.70 Million could theoretically repay 0% of its total liabilities (€7.56 Million) in one year. Check Abionyx Pharma SA cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Abionyx Pharma SA (2013–2024)
Cash flow-to-debt ratio of Abionyx Pharma SA from 2013 to 2024. Historical debt coverage capacity for Abionyx Pharma SA across 12 annual periods. Check Abionyx Pharma SA (ABNX) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Abionyx Pharma SA Cash Flow-to-Debt Ratio by Year (2013–2024)
Abionyx Pharma SA cash flow-to-debt ratio by year from 2013 to 2024. Year-by-year debt coverage analysis for Abionyx Pharma SA. For the full cash flow conversion analysis, see Abionyx Pharma SA (ABNX) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.60x | €-3.60 Million | €6.03 Million | ▼ -11.7% |
| 2023 | -0.54x | €-3.70 Million | €6.91 Million | ▼ -37.8% |
| 2022 | -0.39x | €-3.36 Million | €8.65 Million | ▲ +35.3% |
| 2021 | -0.60x | €-6.69 Million | €11.15 Million | ▼ -266.5% |
| 2020 | -0.16x | €-599.00K | €3.66 Million | ▲ +85.2% |
| 2019 | -1.10x | €-3.95 Million | €3.58 Million | ▼ -70.8% |
| 2018 | -0.65x | €-6.00 Million | €9.30 Million | ▲ +33.2% |
| 2017 | -0.97x | €-9.09 Million | €9.41 Million | ▲ +27.2% |
| 2016 | -1.33x | €-19.20 Million | €14.46 Million | ▼ -25.0% |
| 2015 | -1.06x | €-13.71 Million | €12.91 Million | ▼ -248.1% |
| 2014 | -0.31x | €-3.30 Million | €10.82 Million | ▲ +83.7% |
| 2013 | -1.87x | €-14.49 Million | €7.76 Million | — |